RaQualia Pharma Inc
TSE:4579
RaQualia Pharma Inc
Operating Income
RaQualia Pharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
RaQualia Pharma Inc
TSE:4579
|
Operating Income
-¥337.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Income
¥464.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Income
¥188B
|
CAGR 3-Years
37%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Income
¥294.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
32%
|
CAGR 10-Years
3%
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Income
¥444.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
Astellas Pharma Inc
TSE:4503
|
Operating Income
¥142B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
3%
|
See Also
What is RaQualia Pharma Inc's Operating Income?
Operating Income
-337.4m
JPY
Based on the financial report for Dec 31, 2023, RaQualia Pharma Inc's Operating Income amounts to -337.4m JPY.
What is RaQualia Pharma Inc's Operating Income growth rate?
Operating Income CAGR 10Y
17%
The average annual Operating Income growth rates for RaQualia Pharma Inc have been 11% over the past three years , 21% over the past five years , and 17% over the past ten years .